Trial site
Haematologie-Onkologie im Zentrum MVZ GmbH
Augsburg, 86150, GermanyNot linked to an institution yet
- 12running trials
- 3closed trials
The trials here
What the 15 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 22 trials
- Phase 42 trials
- Phase 1/21 trial
- Status
- Recruiting8 trials
- Active, not recruiting3 trials
- Completed3 trials
- Not yet recruiting1 trial
- Lead sponsor
- AstraZeneca2 trials
- MedSIR2 trials
- AbbVie1 trial
- Astrazeneca AB1 trial
- BioNTech SE1 trial
- and 8 more
Running trials
Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751· Phase 3· BioNTech SE· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· Phase 3· Pfizer· Source
Recruiting
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
NCT06486883· Phase 2· MedSIR· Source
Recruiting
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
NCT06772623· Phase 1/2· AbbVie· Source
Recruiting
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
NCT06201234· Phase 2· GBG Forschungs GmbH· Source
Recruiting
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
NCT06382948· Phase 3· MedSIR· Source
Recruiting
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
NCT06081244· Phase 3· Women's Cancer Study Group GmbH· Source
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751· Phase 3· AstraZeneca· Source
Active, not recruiting
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients with Breast Cancer
NCT06112379· Phase 3· Astrazeneca AB· Source
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654· Phase 3· Gilead Sciences· Source
Recruiting
Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management
NCT05362760· Phase 4· Prof. Wolfgang Janni· Source
Active, not recruiting
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04862663· Phase 3· AstraZeneca· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error